AlphAIAlphAI — Financial news for AI agents
fool.comSEP 12 min read$AMLX

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals (AMLX) has surged 247% this year after positive trial results for its experimental treatment, avexitide, which met all endpoints. The company aims to submit avexitide for FDA approval by year-end, with analysts estimating $1.5B in peak U.S. sales. Amylyx recently raised $500M through a stock offering. The stock is trading at $34.74, with a market cap of $4.2B.

Original reporting
fool.com
Published Sep 1, 2026, 2:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 3:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? — source image
Source · fool.com
Decision brief

The 30-second read

$AMLXBullishMed
01

Why it matters

The Phase 3 data met primary and all secondary endpoints, positioning the company for an FDA filing by year‑end and a possible 2027 launch.

02

Market read

First‑report positive trial data for a mid‑cap biotech in a hot GLP‑1 space, offering a fresh catalyst for traders.

03

What to watch

Potential regulatory delays, competition from other GLP‑1 candidates, and the need for commercial rollout funding.

Relevance 8/10Novelty 8/10Timing: post‑Aug 18 trial announcement

Background

Amylyx (NASDAQ: AMLX) is a biotech focused on rare metabolic disorders. Its prior ALS drug failed in 2024, making the avexitide trial a pivotal turnaround.

Company-level read

Ticker impact

$AMLXBullishHigh confidence
Context

Amylyx announced positive Phase 3 trial results for avexitide, its experimental GLP‑1 therapy for post‑bariatric hypoglycemia.

Expected impact

Potential price rally toward $38‑$40 if market digests the data and FDA filing plans.

Evidence & confidence

Phase 3 success removes a major clinical hurdle and opens a path to FDA submission, a material catalyst for a biotech with no approved therapy in this niche.

Market effects

Sector

Strengthens the GLP‑1 therapeutic segment and may lift peer biotech valuations.

Regional

U.S. biotech market sees renewed interest; no immediate regional spillover.

Global

Adds to global momentum for GLP‑1 drugs, supporting broader pharma sentiment.

Counterpoint

What could challenge this read

The recent $500 M dilution and high valuation may limit upside; price could stall near current levels.

Key entities

  • company
    Amylyx Pharmaceuticals

    Biotech developer of avexitide.

  • analyst
    TD Cowen

    Provided sales estimate of $1.5 B for avexitide.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 1
$AMLXHighAI 8/10

1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals (AMLX) raised $500M, strengthening its balance sheet. Its experimental drug, avexitide, reduced serious hypoglycemic events by 55% in a phase 3 trial, with potential FDA submission by year-end. Analysts estimate peak U.S. sales at $1.5B. The stock has surged 247% year-to-date, but analysts suggest a pullback to $28-$30 per share for better entry.

aol.com2 min
AUG 25
$AMLXMed

Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today?

Amylyx Pharmaceuticals (AMLX) surged 63% after reporting positive Phase 3 trial results for avexitide, with Stifel doubling its price target to $45. Iovance Biotherapeutics (IOVA) hit a 52-week high, driven by Q2 earnings and a price target increase from Mizuho. ONEOK (OKE) reached a 52-week high following strong Q2 earnings, raised 2026 guidance, and a new supply deal, with Morgan Stanley raising its target to $105.

stocktwits.com2 min
AUG 24
$AMLXHighAI 9/10

AMLX Stock Heads For Best Day In Nearly Four Years – Retail Sees Near 70% Upside Potential From Current Levels

Amylyx Pharmaceuticals (AMLX) shares rose 47% after reporting positive Phase 3 trial results for Avexitide, a treatment for post-bariatric hypoglycemia. The drug met primary and secondary endpoints, with plans for FDA submission by 2026. AMLX expects cash to fund operations into 2028, covering a potential 2027 launch. Retail sentiment turned bullish, with some predicting a 70% upside.

stocktwits.com2 min